![](/img/cover-not-exists.png)
A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/− ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy
Lok, A., Willner, I., Reddy, R., Hassan, M., Hinestrosa, F., Shiffman, M., Sulkowski, M., Brown, R., Morelli, G., Peter, J., Fried, M.W., Vainorius, M., Michael, L., Wang, G., Hu, Y., Kort, J., NelsonVolume:
68
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(18)30427-6
Date:
April, 2018
File:
PDF, 46 KB
english, 2018